Anti-PD-1 antibodies and methods of use
Binding molecules targeting PD-1 inhibit its interaction with PD-L1 and PD-L2, addressing the challenge of immune evasion by tumors and enhancing cancer treatment efficacy through immune activation.
WO2026112407A1PCT designated stage Publication Date: 2026-05-28ALMAGRO JUAN CARLOS +1
Patent Information
- Application Number
- PCT/US2025/056530
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-02
- Filing Date
- 2025-11-21
- Publication Date
- 2026-05-28
Smart Images
Figure IMGF000026_0001 
Figure IMGF000027_0001 
Figure IMGF000030_0001
Abstract
Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Combination therapy of t cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
US20210087291A1
Asgpr antibodies and uses thereof
WO2014023709A1